ClinicalTrials.gg
RecruitingNCT07653620Updated Sep 21, 2026

Hydration & Female Life Stages

An interventional study of placebo beverage and electrolyte beverage in Dehydration, Menstruation and Pre-menopause, sponsored by PepsiCo Global R&D. Recruiting at 2 sites in United States. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by PepsiCo Global R&D (part of PepsiCo, Inc.) · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Female
01

Study summary

Female life stages including premenopausal, perimenopausal, postmenopausal, are characterized by changing concentrations and patterns of hormones. The premenopause stage represents the reproductive years with normal menstrual cycles lasting between 21-35 days. The perimenopause stage is the beginning of the menopause transition and can last up to 10 years. During this transition, menstrual cycles become longer and irregular in length (7 days or longer). After 12 consecutive months with no period, the transition is complete into the postmenopause stage.

Hormones that change across the lifespan are known to influence systems that regulate thirst, fluid balance, and sodium balance. Yet, fluid balance across life stages remains poorly understood, with no direct comparisons across all three life stages. The purpose of this study is to evaluate the effect of female life stage on rehydration with water and electrolyte solution after overnight fast and fluid restriction

02

Conditions studied

  • Dehydration
  • Menstruation
  • Pre-menopause
  • Peri-menopausal Women
  • Post-menopausal Women
  • Hydration

Browse trials for

03

In context

Dehydration

201 studies on the registry are indexed under Dehydration; 28 are open to participants now.

This study's planned enrollment of 72 is above the median of 43 across 145 interventional studies indexed under Dehydration.

Browse Dehydration studies →

Lead sponsor

PepsiCo Global R&D is the lead sponsor of 103 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Sex assigned female at birth.

      • Recreationally active (engaged in light to moderate-intensity, intermittent, or steady-state exercise at least 3 days per week for at least 30 min at a time)
      • Age 18-60 years, within the following life stage ranges specified below:
      • Premenopausal:

        • 18-35 years
        • Self-report regular spontaneous menstrual cycle length (21-35 days) for the past 2 menstrual cycles
        • Menstrual cycle length \< 7 days variation in consecutive cycles
      • Perimenopausal:

        • Perimenopause: 35-55 years
        • If tracking cycles: self reported cycle irregularity (≥7 day difference from usual cycle length) for the past 2 menstrual cycles, not due to known pathology
        • If not tracking cycles: clinician diagnosis
      • :

        • Postmenopause: 45-60 years
        • If tracking cycles: ≥12 consecutive months of spontaneous amenorrhea not due to pregnancy, lactation, or pathology
        • If not tracking cycles: clinician diagnosis
      • Healthy, with no known renal, cardiovascular, metabolic, or endocrine disorders that affect hydration or fluid regulation.
      • Not currently taking medications known to influence fluid balance (e.g., diuretics, laxatives, weight loss agents, or other relevant medications) or the hypothalamus-pituitary-gonadal axis (e.g., ovulation induction agents, gonadotropins, IVF stimulation medications, or other relevant medications)

        o See appendix 13.8 for list of medications, drugs, and/or medical conditions that may impair cognitive functioning, alter physiological responses relevant to the study outcomes, or increase the risk associated with participation.

      • Not receive any fertility treatments within the past 6 months
      • No hormonal use within the past 6 months
      • If using a paraguard copper IUD, it must be inserted for ≥ 3 months (if applicable)
      • ≤ 30 kg/m²
      • Are not participating in a weight loss program
      • Are not allergic to adhesives, stevia, and strawberry lime flavoring
      • Willing to avoid strenuous activity and alcohol consumption 24 hours prior to all visits
      • Willing to fast overnight (\~12 hours) prior to the medical screening
      • For visit 2 and 4:

        • Willing to fast overnight (\~12 hours)
        • Willing to consume a minimum of 2.7 L of water 24 hours prior to visits 2 and 4, then 500 mL 2 hours before the start of the visits 2 and 4
      • For visits 3 and 5:
      • Willing to restrict all fluids (\~18 hours)
      • Willing to limit fluid consumption to 1 L the morning/afternoon prior to the start of the fluid restriction
      • Willing to restrict food (\~12 hours) the day prior to each visit Willing to eat a consistent diet the day prior
      • Fluent in English (able to read, understand, and provide ).
      • Willing and able to provide informed consent to participate in the study and comply with all study procedures and scheduled visits

Exclusion criteria

Exclusion Criteria:

    • Currently pregnant or breastfeeding

      • \< 6 months since giving birth (even if experiencing 2 regular menstrual cycles in a row)
      • Smoking within the last 5 years
      • History of adverse events (e.g., fainting) with blood draws
      • Participants with large amount of internal metal (e.g., spinal rod) will be excluded from the DXA scan only (Brandenton)
      • Participant has participated in a clinical trial within the past 30 days
      • Participant has participated in any PepsiCo trial within past 3 months
      • Participant has a condition or is taking medication that the investigator believes would interfere with his/her ability to provide , comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk
      • Participant is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If participant is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Beverage

    Other: placebo beverage

  • Experimental
    Electrolyte Beverage

    Other: electrolyte beverage

Interventions

  • Otherplacebo beverage

    333 mL aliquots 3 times for a total of 1 L over a 30 min period. Time 0 begins post-dose.

  • Otherelectrolyte beverage

    333 mL aliquots 3 times for a total of 1 L over a 30 min period. Time 0 begins post-dose. Beverage matched to placebo for color and flavor.

06

What researchers measure

Primary outcomes

  1. Fluid Balance

    calculated as change in nude body mass from baseline (%)

    Time frame: Change from baseline, 4 hours

Secondary outcomes

  1. Fluid Balance

    calculated as change in nude body mass from baseline (g)

    Time frame: Change from baseline, 4 hours

  2. Urine Mass

    g

    Time frame: Change from baseline, 4 hours

  3. Urine Specific Gravity

    au

    Time frame: Change from baseline, 4 hours

  4. Urine Osmolality

    mosmol/kg

    Time frame: Change from baseline, 4 hours

  5. Fluid Retention

    Percentage (%)

    Time frame: Change from baseline, 4 hours

  6. Free Water Clearance

    ml/min

    Time frame: Change from baseline, 4 hours

  7. Whole blood sodium concentration

    mmol/L

    Time frame: Change from baseline, 4 hours

  8. Whole blood potassium concentration

    mmol/L

    Time frame: Change from baseline, 4 hours

  9. Whole blood glucose concentration

    mg/dl

    Time frame: Change from baseline, 4 hours

  10. Whole blood hematocrit

    Percentage (%)

    Time frame: Change from baseline, 4 hours

  11. Whole blood hemoglobin concentration

    g/dl

    Time frame: Change from baseline, 4 hours

  12. Serum osmolality

    mosmol/kg

    Time frame: Change from baseline, 4 hours

  13. Serum copeptin concentration

    pmol/L

    Time frame: Change from baseline, 4 hours

  14. Serum estrogen

    pg/mL

    Time frame: Change from baseline, 4 hours

  15. Serum progesterone

    ng/mL

    Time frame: Change from baseline, 4 hours

  16. Serum follicle stimulating hormone (FSH)

    pg/mL

    Time frame: Change from baseline, 4 hours

  17. Capillary follicle stimulating hormone (FSH)

    MIU/mL

    Time frame: At baseline, to determine menstruation status

  18. Salivary Cortisol

    ng/mL

    Time frame: Change from baseline, 4 hours

  19. Salivary Estradiol

    pg/mL

    Time frame: Change from baseline, 4 hours

  20. Salivary Progesterone

    pg/mL

    Time frame: Change from baseline, 4 hours

  21. Low energy availability Questionnaire (LEAF-Q)

    Validated questionnaire that assesses injury, gastrointestinal symptoms, and menstrual function, score \> 8 at risk for LEA

    Time frame: at screening to determine menstrual history

  22. Menopause Rating Scale (MRS)

    5-point likert scale assessing symptoms as none (0) to very severe (4), \> score mean more severe/greater number of symptoms

    Time frame: at baseline to determine menopause symptoms

  23. Feeling Scale (FS)

    11-point scale assessing changes in mood ranging from very good (5) to very bad (-5), positive score is associated with positive affect

    Time frame: change from baseline, 4 hours

  24. Gastrointestinal discomfort and headache (VAS)

    100-pt visual analog scale anchored from none (0) to severe (100), \> score is associated with increased symptoms

    Time frame: change from baseline, 4 hours

  25. Mental and physical energy and fatigue (VAS)

    100-pt visual analog scale anchored from none (0) to severe (100), \> score is associated with stronger feelings

    Time frame: change from baseline, 4 hours

  26. Blood Pressure

    systolic/diastolic, mm/Hg

    Time frame: Change from baseline, 4 hours

  27. Heart Rate

    Beats per minute (BPM)

    Time frame: Change from baseline, 4 hours

  28. Adverse Events

    Documented changes in health and symptoms as a safety measurement

    Time frame: Through study completion, an average of 4 weeks for pre- and peri-menopausal subjects and 2 weeks for post-menopausal subjects.

07

Study locations

2 of 2 sites recruiting
  • GSSI Bradenton
    Bradenton, Florida 34210, United States
    Recruiting
  • GSSI Valhalla
    Valhalla, New York 10595, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07653620
Lead sponsor
PepsiCo Global R&D
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jun 29, 2026
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 21, 2026

Study contacts

Samantha Goldenstein
Contact
GatoradeGSSIIMG@pepsico.com
847-707-3118
Susan Kwiecien
Contact
GSSIresearchstaff@pepsico.com
847-707-3118

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion